BioAge Labs suffered a dramatic pre-market decline, with its shares falling 51.9% after Novo Nordisk disclosed that ziltivekimab failed to lower the rate of major adverse cardiovascular events compared with placebo in the Phase 3 ZEUS trial. The ZEUS study enrolled patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated markers of inflammation.
Investigators reported that ziltivekimab demonstrated target engagement and suppression of the IL-6 pathway, but the clinical outcome produced a hazard ratio effectively equal to 1.0. That metric indicates the treatment did not produce a meaningful reduction in cardiovascular risk despite achieving its biological effect.
The implications for BioAge are immediate and material. BioAge’s lead candidate, BGE-102, is an oral NLRP3 inhibitor now under evaluation in the QUELL-CV Phase 2 trial in patients at elevated cardiovascular risk - effectively the same therapeutic area and patient population addressed by ZEUS. Because the two programs share a mechanistic rationale focused on inflammatory pathways, the negative ZEUS readout represents a direct read-through and has sharply diminished investor confidence in the prospect that inflammation-targeting strategies can deliver cardiovascular outcomes.
Monte Rosa Therapeutics also came under pressure in the selloff, cited for exposure to similar mechanistic or therapeutic themes.
Market context was notable: the selloff in BIOA occurred despite a broadly constructive session for U.S. equity benchmarks. The S&P 500 rose 0.3%, the Dow Jones Industrial Average added 0.5%, and the Nasdaq gained 1.0%, indicating the BIOA decline was driven by the trial news and its specific read-through rather than a general market downturn.
Before the pre-market collapse, BioAge had been trading close to its 52-week high of $25.96, supported by analyst buy ratings and encouraging Phase 1 data for BGE-102. On the day of the trial announcement BIOA traded near $11.96, substantially above its 52-week low of $4.11 but well below recent highs. The sudden move has prompted investors to reassess the odds that BGE-102’s QUELL-CV trial can achieve positive cardiovascular outcomes where the well-resourced ZEUS program did not.
In sum, a high-profile Phase 3 failure in an adjacent program, shared mechanistic logic, and a stock that had advanced into the event combined to produce an outsized pre-market drop in BioAge. The ZEUS result calls into question the broader hypothesis that upstream inflammatory pathway inhibition will translate into measurable cardiovascular benefit, a premise at the core of BioAge’s investment case.